Turn Therapeutics Inc. Common Stock
$14.94
$1.12 (+8.10%)
$13.80Day Range$16.45
Key Statistics
Market Cap
$419.68M
Shares Outstanding
30.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 8, 2025
Round Lot
100
Locale
US
Trading Data
Day Open
$13.80
Day High
$16.45
Day Low
$13.80
Volume
930.0K
VWAP
$15.11
Prev Close
$13.82
Transactions
--
Acc. Volume
--
About Turn Therapeutics Inc. Common Stock
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
PHARMACEUTICAL PREPARATIONSSIC 28342 employees250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE, CA, 91362(818) 564-4011IPO Oct 8, 2025US / STOCKSActiveWebsite
Identifiers
- CIK
- 0002023016
- Composite FIGI
- BBG002QTLH75
- Share Class FIGI
- BBG002QTLH84
- Ticker Root
- TTRX
- SIC Code
- 2834
About Turn Therapeutics Inc. Common Stock (TTRX) Stock
Turn Therapeutics Inc. Common Stock (TTRX) closed the 2026-09-18 session at $14.94, up 8.10% versus the previous close (+1.12). The stock opened at $13.80 and traded between $13.80 and $16.45 during that session. Session trading volume was 930K shares. The volume-weighted average price (VWAP) is $15.11.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
Turn Therapeutics Inc. Common Stock has a market capitalization of $419.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. TTRX is listed on the XNAS exchange. The company employs approximately 2 people. Turn Therapeutics Inc. Common Stock is headquartered in WESTLAKE VILLAGE, CA. The recorded listing date is 2025-10-08.
On this page you can find market TTRX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.